FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients two years of age and older.¹Post hoc analysis of patients with LGS, transitioning from the randomized controlled trial to an open-label extension study, who started FINTEPLA following placebo and those who continued with FINTEPLA showed rapid improvement in seizure frequency and global functioning.²Rapid clinical improvement in seizure frequency and global functioning were observed in both groups, as mean Fintepla dose was increased.²Safety findings were consistent with known data, with expected increases in common adverse events following FINTEPLA initiation and decreasing incidence over time with continued treatment.²These results showed that sustained FINTEPLA treatment is effective and tolerable.²